The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.
 
Stephanie Blankenstein
No Relationships to Disclose
 
Maureen J.B. Aarts
Consulting or Advisory Role - Astellas Amgen BioPharama (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
 
Franchette van den Berkmortel
No Relationships to Disclose
 
Marye Boers-Sonderen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst)
 
Alfonsus Johannes Maria van den Eertwegh
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Bristol-Myers Squibb; Roche; Sanofi
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche; Sanofi
 
Margreet G. Franken
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Pamgene (Inst); Roche (Inst)
 
Jan Willem de Groot
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); SERVIER (Inst)
 
John B. A. G. Haanen
Consulting or Advisory Role - AIMM Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celsius Therapeutics (Inst); Gadeta (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Ipsen (Inst); Merck Serono (Inst); MSD (Inst); Neogen (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); VAXIMM (Inst)
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Geke Hospers
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Seerave Foundation (Inst)
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Pierre Fabre (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Roche
 
Djura Piersma
No Relationships to Disclose
 
Rozemarijn Van Rijn
No Relationships to Disclose
 
Karijn Suijkerbuijk
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst)
Speakers' Bureau - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD (Inst); Roche (Inst)
 
Albert J. ten Tije
Consulting or Advisory Role - Bristol-Myers Squibb
 
Astrid Aplonia Maria Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Novartis; Roche; Roche
 
Gerard Vreugdenhil
No Relationships to Disclose
 
Michel W.J.M. Wouters
No Relationships to Disclose
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis